Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GPhA adds lobbyist

Executive Summary

Generic Pharmaceutical Association's chief federal lobbyist will be Stephen Mason, who joins as director-federal government affairs. Mason was formerly federal legislative director for the Health Insurance Association of America, which recently merged with the American Association of Health Plans (1"The Pink Sheet" Dec. 15, 2003, In Brief). Mason brings experience working with Republican officials and candidates, including Sen. John Ensign (R-Nev.)...

You may also be interested in...



AAHP-HIAA completes merger

American Association of Health Plans and Health Insurance Association of America complete merger Dec. 11; the association will be known temporarily as AAHP-HIAA. The association is also moving its Washington, D.C. headquarters to 601 Pennsylvania Ave., NW. AAHP CEO Karen Ignagni will continue as head of the combined group (1"The Pink Sheet" Sept. 29, 2003, p. 14)...

Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel

Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.

US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says

The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043620

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel